Clinical Trials on Prostate Cancer Metastatic in United Kingdom

Total 26080 results

Duke University
United States Department of Defense

Completed

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Metastatic Hormone Refractory Prostate Cancer

United States
National Cancer Institute (NCI)

Enrolling by invitation

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center; University of California, San Francisco

Active, not recruiting

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT)

Solid Tumor | Metastatic Cancer | Metastatic Castration Resistant Prostate Cancer

United States
Pellficure Pharmaceuticals, Inc

Terminated

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Dana-Farber Cancer Institute
Progenics Pharmaceuticals, Inc.

Not yet recruiting

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Carcinoma

United States
University Hospital Birmingham

Completed

Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy

Prostate Cancer | Metastatic Cancer

United Kingdom
Paul Mathew, MD
Hoosier Cancer Research Network; Tesaro, Inc.

Terminated

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Metastatic Prostate Cancer

United States
University of Wisconsin, Madison
Prostate Cancer Foundation; Madison Vaccines, Inc

Completed

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; Puma Biotechnology, Inc.

Withdrawn

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma

United States
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
Exosome Diagnostics, Inc.
Yale University

Suspended

Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)

Metastatic Castrate Resistant Prostate Cancer

United States
Jodi Layton, MD
EMD Serono

Terminated

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Metastatic Castration-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

Pain | Prostate Cancer | Metastatic Cancer

United States
Sanofi

Completed

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (TAXYNERGY)

Prostate Cancer Metastatic

United States, Canada
University of Texas Southwestern Medical Center

Completed

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

mCRPC | Metastatic Castrate-resistant Prostate Cancer

United States
GenesisCare USA
Dendreon

Completed

A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

Castrate Refractory Metastatic Prostate Cancer (mCRPC)

United States
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Metastatic Progressive Castration-resistant Prostate Cancer

United States
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
Amgen

Terminated

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States, Sweden, Spain, United Kingdom, Australia, Denmark
Astellas Pharma Global Development, Inc.
Pfizer

Completed

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) (TRUMPET)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Oregon Health and Science University

Completed

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Prostate Cancer | Metastatic, Androgen Independent Prostate Cancer

United States
Duke University
Bayer

Completed

Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer

Bone Metastatic Castration-Resistant Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Prostate Cancer | Metastatic Cancer

United States
Julie Graff, MD
Johns Hopkins University; Merck Sharp & Dohme LLC; Oregon Health and Science... and other collaborators

Recruiting

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Prostate Cancer | Prostate Cancer Metastatic

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer

Metastatic Prostate Cancer

United States
Global Isotopes, LLC d/b/a Zevacor Molecular

Completed

Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

Metastatic Prostate Cancer

United States
UNC Lineberger Comprehensive Cancer Center

Withdrawn

Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Prostate Cancer | Metastatic Cancer

United States
Rashmi Verma, MD
National Cancer Institute (NCI)

Recruiting

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Zenith Epigenetics

Completed

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Royal Marsden NHS Foundation Trust
Institute of Cancer Research, United Kingdom; National Institute for Health...

Active, not recruiting

Whole Body Magnetic Resonance Imaging Study (WISE)

Advanced Prostate Cancer

United Kingdom
University of Alabama at Birmingham
Amgen

Completed

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Metastatic Castration-resistant Prostate Cancer

United States
Rahul Aggarwal
Sanofi

Completed

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Duke University

Completed

EXTEND Exercise Trial

Non-metastatic, Hormone naïve Prostate Cancer

United States
BAMF Health

Recruiting

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) (SPECTacular)

Metastatic Castration-resistant Prostate Cancer

United States
Zenith Epigenetics

Completed

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Cambridge University Hospitals NHS Foundation Trust

Unknown

Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer (CAMPROBE)

Prostate Cancer | Prostate Biopsy

United Kingdom
AstraZeneca

Completed

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer (Capri)

Non-Metastatic Prostate Cancer

Czech Republic, Italy, South Africa, United Kingdom, Germany, Poland, Netherlands, Austria, Belgium, Hungary, Israel, Portugal, Mexico, Spain, Australia, Ireland
Dizal Pharmaceuticals

Terminated

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Metastatic Castration Resistant Prostate Cancer

United States, Korea, Republic of
Eli Lilly and Company
Sarah Cannon Development Innovations

Completed

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Prostate Cancer Metastatic

United States
US Oncology Research
Pfizer

Completed

Phase II Sunitinib Prog Met AIPC

Metastatic Prostate Cancer

United States
Bayer

Completed

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (EPIX)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Christopher Sweeney, MBBS
Sanofi; Hoosier Cancer Research Network; Walther Cancer Institute

Terminated

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Metastatic Prostate Cancer

United States, Canada
Bavarian Nordic

Completed

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)

Prostate Cancer Metastatic

United States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
Bayer

Active, not recruiting

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

Bone Metastatic Castration-resistant Prostate Cancer

France, Lithuania, Israel, Italy, United Kingdom, Austria
University of California, San Francisco
Merck Sharp & Dohme LLC; Prostate Cancer Foundation

Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

United States
AstraZeneca
Bayer

Recruiting

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Metastatic Prostate Cancer

Italy, United Kingdom, Australia, United States
Arvinas Androgen Receptor, Inc.

Active, not recruiting

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Metastatic

Canada, United States, France, United Kingdom
Gilead Sciences

Terminated

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Metastatic Castrate-Resistant Prostate Cancer

United States

Clinical Trials on Prostate Cancer Metastatic in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations